Review
doi: 10.1212/01.wnl.0000052681.28286.52.
Initial agonist treatment of Parkinson disease: a critique
Affiliations
- PMID: 12580185
- DOI: 10.1212/01.wnl.0000052681.28286.52
Item in Clipboard
Review
Initial agonist treatment of Parkinson disease: a critique
Neurology.
.
Abstract
The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.
Comment in
-
Agonists vs levodopa in PD: the thrilla of whitha.Neurology. 2003 Feb 11;60(3):360-2. doi: 10.1212/wnl.60.3.360. Neurology. 2003. PMID: 12578913 No abstract available.
-
Agonists versus levodopa in PD: the thrilla of whitha.Neurology. 2003 Nov 25;61(10):1462; author reply 1462-3. doi: 10.1212/wnl.61.10.1462. Neurology. 2003. PMID: 14638991 No abstract available.
-
Slowing Parkinson's disease progression: recent dopamine agonist trials.Neurology. 2004 Jan 27;62(2):343; author reply 343-5. Neurology. 2004. PMID: 14745094 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
